Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2025-12-25 @ 4:03 AM
NCT ID:
NCT00542802
Eligibility Criteria:
Inclusion Criteria:
* Patients having a stroke (ischemic and haemorrhagic) showing (one) subsequent seizure 14 days up to 3 years after stroke
* Patients has signed the informed consent form
* Aged ≥ 18 years
Exclusion Criteria:
* Severe stroke patients with Rankin scale \> 3
* Patients with a life expectancy of \< 12 months
* Patients screened more than 15 days after first seizure
* Patients with a diagnosed epilepsy
* Patients with clear evidence of myoclonic seizures
* Patients with contraindication to levetiracetam and carbamazepine use
* Patients presenting epileptic status at onset
* Patients having a MMSE \<24
* Patients having a seizure before stroke
* Patients taking any AED 4 weeks prior to randomisation in the study
* Patients showing dysphagia after stroke not able to swallow tablets.
* Patients with a low compliance for the study
* Pregnant women, lactating or sexually active women with childbearing potential who are not using a medically accepted birth control method.
* Allergy or intolerance to pyrrolidine derivatives and/or tablet excipients or to carbamazepine derivates and /or tablet excipients
* Patients involved in another clinical trial 30 days prior randomization
* Patients with any tumour
* Patients with previous traumatic brain accident resulting in impairment of consciousness.
* Patients for whom it is not possible to assess seizure onset
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00542802
Study Brief:
Protocol Section:
NCT00542802